Chen, Jinyun <br/><br/>
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.  [electronic resource] 

 -  Annals of surgical oncology  Feb 2009 
 - 431-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1534-4681 
<br/><br/><label>Standard No.: </label>10.1245/s10434-008-0220-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--genetics<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Pancreatic Ductal--genetics<br/>Chemotherapy, Adjuvant<br/>Cisplatin--administration & dosage<br/>Combined Modality Therapy<br/>Cyclin-Dependent Kinase Inhibitor p16<br/>Cyclin-Dependent Kinase Inhibitor p27--genetics<br/>DNA-Binding Proteins--genetics<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Proteins--genetics<br/>Nuclear Proteins--genetics<br/>Pancreatic Neoplasms--genetics<br/>Pancreaticoduodenectomy<br/>Polymorphism, Single Nucleotide--genetics<br/>Prognosis<br/>Proto-Oncogene Proteins c-mdm2--genetics<br/>Radiotherapy, Adjuvant<br/>Survival Rate<br/>Time Factors<br/>Tumor Protein p73<br/>Tumor Suppressor Proteins--genetics<br/>Gemcitabine